A new therapy for breast cancer is being designed using wasp venom

August 5, 2014, Plataforma SINC
Credit: Ferrán Pestaña

Scientists from the Institute for Biomedical Research (IRB Barcelona) have carried out successful in vitro tests using wasp venom to kill tumour cells. The next step will be to test its efficacy in mouse models.

Despite there currently being a wide variety of compounds against cancer, they all have serious side effects. Furthermore, tumours are capable of becoming resistant, limiting this type of treatment.

In order to counteract these two disadvantages, scientists from the Institute for Biomedical Research (IRB Barcelona) have designed a new therapy based on a peptide - the binding of several - from wasp venom for its potential use against .

"This peptide has the ability to form pores in the cell plasma membrane, penetrate into the cell and finally, cause its death, either by necrosis or by triggering apoptosis, programmed cell death", Miguel Moreno, lead author of IRB Barcelona explained to Sinc.

However, this powerful 'natural weapon' could not be used due to its high toxicity and lack of cell specificity; that is, it would not only damage tumour cells but would also affect healthy patient cells. As such, the researchers designed a means of transporting the peptide to the tumour and making it accumulate in a specific and controlled manner.

The system consists of a decorated carrier polymer with two components: a peptide that is bound to a tumour cell receptor and the cytotoxic peptide of the wasp venom.

In vitro experiments show that the substance is adequately distributed within the and causes their death, while , such as , are not affected.

Although the results, which have been published in the Journal of Controlled Release, seem to be promising, they are still in their very early stages. The next step is to test their efficacy through in vivo tests in mice. The authors are very optimistic that the research will be successful and this anti-tumour system may be used in the future as a supplementary therapy to those already in existence.

Cancer, a challenge for scientists

Cancer is one of the main causes of death worldwide. For experts, epidemiological trends continue to be alarming given the increases in the rates of incidence and mortality.

Nowadays, tumours are treated with radiotherapy, surgery and chemotherapy. The side effects derived from anti-tumour compounds are a result of their low specificity.

Explore further: Scientist discovers new target for cancer therapy

More information: Moreno M, Zurita E, Giralt E. "Delivering wasp venom for cancer therapy." J Control Release. 2014 May 28;182:13-21. DOI: 10.1016/j.jconrel.2014.03.005. Epub 2014 Mar 12.

Related Stories

Scientist discovers new target for cancer therapy

January 24, 2013
Tumour cells need far more nutrients than normal cells and these nutrients cannot get into the malignant cells without transporters.

Brain tumour cells killed by anti-nausea drug

March 18, 2013
(Medical Xpress)—New research from the University of Adelaide has shown for the first time that the growth of brain tumours can be halted by a drug currently being used to help patients recover from the side effects of ...

Researchers identify a new suppressor of breast metastasis to the lung

May 27, 2014
A study published today in EMBO Molecular Medicine reveals that the loss of function of the gene RARRES3 in breast cancer cells promotes metastasis to the lung.

Cancer's growth driven by minority of cells within a tumour

July 31, 2014
US cancer researchers have unearthed further evidence that a tumour's growth can be fuelled by just a small minority of its cells.

New research reveals how cannabis compound could slow tumour growth

July 14, 2014
Scientists at the University of East Anglia have shown how the main psychoactive ingredient in cannabis could reduce tumor growth in cancer patients.

Chemotherapy and herpes can help fight cancer, study finds

November 20, 2013
(Medical Xpress)—Combining chemotherapy with a herpes virus has shown promise in killing cancer cells and tumours during initial testing, two complementary McMaster studies have found.

Recommended for you

Researchers develop a remote-controlled cancer immunotherapy system

January 15, 2018
A team of researchers has developed an ultrasound-based system that can non-invasively and remotely control genetic processes in live immune T cells so that they recognize and kill cancer cells.

Pancreatic tumors may require a one-two-three punch

January 15, 2018
One of the many difficult things about pancreatic cancer is that tumors are resistant to most treatments because of their unique density and cell composition. However, in a new Wilmot Cancer Institute study, scientists discovered ...

New immunotherapy approach boosts body's ability to destroy cancer cells

January 12, 2018
Few cancer treatments are generating more excitement these days than immunotherapy—drugs based on the principle that the immune system can be harnessed to detect and kill cancer cells, much in the same way that it goes ...

Cancer's gene-determined 'immune landscape' dictates progression of prostate tumors

January 12, 2018
The field of immunotherapy - the harnessing of patients' own immune systems to fend off cancer - is revolutionizing cancer treatment today. However, clinical trials often show marked improvements in only small subsets of ...

FDA approves first drug for tumors tied to breast cancer genes

January 12, 2018
(HealthDay)—The U.S. Food and Drug Administration on Friday approved the first drug aimed at treating metastatic breast cancers linked to the BRCA gene mutation.

Breast cancer gene does not boost risk of death: study

January 12, 2018
Young women with the BRCA gene mutation that prompted actress Angelina Jolie's pre-emptive and much-publicised double mastectomy are not more likely to die after a breast cancer diagnosis, scientists said Friday.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.